Novel Pharmaceutical Compounds

A compound of structural Formula I

• and the pharmaceutically acceptable salts, esters and solvates thereof wherein:
• is selected from the group consisting of
• wherein the numbers “1” and “2” indicate the points of attachment within structural Formula I;
• A is selected from the group consisting of —Cl and phenyl optionally mono- or di-substituted with a substituent independently selected at each occurrence from the group consisting of (i) —F (ii) —Cl, (iii) —C1-3alkyl optionally substituted with one or more of halo, (iv) —OC1-3alkyl optionally substituted with one or more of halo, (v) —OC3-6cycloalkyl, (vi) —C3-6cycloalkyl, (vii) —CH2OH, (viii) —COOR5, (ix) —CN and (x) —NR5R5a;
• n is an integer selected from zero, 1 and 2;
• R1 is selected from the group consisting of (i) —H, (ii) —Br, (iii) —Cl, (iv) —COC1-6alkyl, (v) —COOC1-6alkyl, (vi) —COOC3-6cycloalkyl, (vii) —SO2C1-6alkyl, (viii) —SO2NR5R5, (ix) —CONR5R5, (x) —CN, (xi) —C1-6alkyl optionally mono- or di-substituted with a substituent independently selected at each occurrence from the group consisting of —OH and —F, (xii) phenyl optionally mono- or di-substituted with a substituent independently selected at each occurrence from the group consisting of —OH and —F, (xiii) tetrazolyl optionally substituted with methyl, (xiv) 1,2,4-oxadiazolyl optionally substituted with methyl, and (xv) pyridinyl optionally substituted with methyl;
• R2 is selected from the group consisting of —H, —OH, —F, —C1-3alkyl, —OC1-3alkyl and —OC(O)—C1-3alkyl;
• R3 is selected from the group consisting of —H, —C1-6alkyl, —C1-6alkyl substituted with one or more of fluoro, —C1-6alkyl substituted with R6, phenyl, —C2-6alkenyl, —C3-6cycloalkyl and —C5-7cycloalkenyl;
• R4 is selected from the group consisting of —H, —C1-6alkyl, —C1-6alkyl substituted with one or more of fluoro, —C1-6alkyl substituted with R6, phenyl, —C2-6alkenyl, —C3-6cycloalkyl and —C5-7cycloalkenyl;
• R5 is independently selected at each occurrence from the group consisting of —H, —C1-6 alkyl and —C3-6cycloalkyl;
• R5a is independently selected at each occurrence from the group consisting of —H, —C1-6 alkyl, —C3-6cycloalkyl and —COOR5;
• and
• R6 is independently selected at each occurrence from the group consisting of —COOR5, —C(O)H, —CN, —CR5R5OH, —OR5, —S—C1-6alkyl and —S—C3-6 cycloalkyl.